Skip to main content
SpringerLink
Log in

Gewinnung und Präparation von peripheren Blutstammzellen

  • Chapter
Transfusionsmedizin und Immunhämatologie

Zusammenfassung

Die Möglichkeit, periphere Blutstammzellen durch Wachstumsfaktoren zu mobilisieren und in großer Menge durch Zytaphereseverfahren zu gewinnen, hat neue Perspektiven eröffnet und ist inzwischen ein Standardverfahren sowohl für die autologe als auch für die allogene Transplantation hämatopoetischer Vorläuferzellen. Blutstammzellen sind im Vergleich zu Knochenmark einfacher und ohne Narkose zu gewinnen, bieten eine höhere Vorläuferzellzahl, führen zu einer rascheren hämatologischen und immunologischen Rekonstitution nach Transplantation und erleichtern neue Behandlungsstrategien mit In-vitro-Manipulation des Transplantates bis hin zur zellulären Immuntherapie und Gentherapie.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Anderlini P, Przepiorka D, Seong D, et al. (1996) Clinical toxicity and laboratory effects of granulocyte colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors and analysis of charges for the procedures. Transfusion 36:590–595

    Article  PubMed  CAS  Google Scholar 

  2. Anderlini P, Przepiorka D, Lauppe J, et al. (1997) Collection of peripheral blood stem cells from normal donors 60 years of age or older. Br J Haematol 97:485–487

    Article  PubMed  CAS  Google Scholar 

  3. Bahçeci E, Read EJ, Leitman S, et al. (2000) CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies. Brit J Haematol 108:408–414

    Article  Google Scholar 

  4. Bender JG, To LB, Williams SF, Schwartzberg L (1992) Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1:329–341

    Article  PubMed  CAS  Google Scholar 

  5. Bender JG, Lum L, Unverzagt KL, et al. (1994) Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens. Bone Marrow Transplant 13:479–485

    PubMed  CAS  Google Scholar 

  6. Bensinger WI, Storb R (2001) Allogeneic peripheral blood stem cell transplantation. Rev Clin Exp Hematol 5:67–86

    Article  PubMed  CAS  Google Scholar 

  7. Bensinger WI, Longin K, Appelbaum F, et al. (1994) Peripheral blood stem cells collected after recombinant garnulocyte stimulating factor: an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 87:825–831

    Article  PubMed  CAS  Google Scholar 

  8. Bensinger WI, Appelbaum F, Rowley S, et al. (1995) Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547–2555

    PubMed  CAS  Google Scholar 

  9. Bensinger W, DiPersio JF, McCarty JM (2009) Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 43:181–195

    Article  PubMed  CAS  Google Scholar 

  10. Bethge WA, Faul C, Bornhäuser M, et al. (2008) Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: An update. Blood Cells, Molecules, and Diseases 40:13–19

    Article  PubMed  CAS  Google Scholar 

  11. Bönig H, Wundes A, Chang KH (2008) Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 111:3439–3441

    Article  PubMed  CAS  Google Scholar 

  12. Bond VP, Cronkite EP, Fliedner TM, et al. (1958) Deoxyribonucleic acid synthesizing cells in peripheral blood of normal human beings. Science 128:202–203

    Article  PubMed  CAS  Google Scholar 

  13. Broxmeyer HE, Lu L, Cooper S, et al. (1995) Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp Hematol 23:1121–1129

    PubMed  CAS  Google Scholar 

  14. Brugger W, Bross KJ, Glatt M, et al. (1994) Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83:636–640

    PubMed  CAS  Google Scholar 

  15. Calvo W, Fliedner TM, Herbst E, et al. (1967) Regeneration of bloodforming organs after autologous leukocyte transfusion in lethally irradiated dogs. II. Distribution and cellularity of the marrow in irradiated and transfused animals. Blood 47 (Suppl 4):593–601

    Google Scholar 

  16. Cavins JS, Scheer SC, Thomas ED, Ferrebee JW (1964) The recovery of lethally irradiated dogs given infusions of autologous leukocytes preserved at –80 °C. Blood 23:38–43

    PubMed  CAS  Google Scholar 

  17. Cebon J, Layton JE, Maher D, Morstyn G (1994) Endogenous haematopoietic growth factors in neutropenia and infection. Br J Haematol 86:265–274

    Article  PubMed  CAS  Google Scholar 

  18. Champlin R, Schmitz N, Horowitz M, et al. (2000) Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 95:3702–3709

    PubMed  CAS  Google Scholar 

  19. Clark RE, Brammer CG (1998) Previous treatment predicts the efficiency of blood progenitor cell mobilization: validation of a chemotherapy scoring system. Bone Marrow Transplant 22:859–863

    Article  PubMed  CAS  Google Scholar 

  20. Demirkazik A, Kessinger A, Armitage JO, et al. (2001) Progenitor and lymphoma cells in blood stem cell harvests: impact on survival following transplantation. Bone Marrow Transplant 28:207–212

    Article  PubMed  CAS  Google Scholar 

  21. Dercksen MW, Rodenhuis S, Dirkson MKA, et al. (1995) Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. J Clin Oncol 13:1922–1932

    PubMed  CAS  Google Scholar 

  22. Desikan KR, Tricot G, Munshi NC, et al. (2001) Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol 112:242–247

    Article  PubMed  CAS  Google Scholar 

  23. DiPersio JF, Stadtmauer EA, Nademanee A, et al. (2009) Plerixaflor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113:5720–5726

    PubMed  CAS  Google Scholar 

  24. Drake M, Ranaghan L, Morris TC, et al. (1997) Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol 98:745–749

    Article  PubMed  CAS  Google Scholar 

  25. Dreger P, Suttorp M, Haferlach T, et al. (1993) Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 81:1404–1407

    PubMed  CAS  Google Scholar 

  26. Dreger P, Haferlach T, Eckstein V, et al. (1994) G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 87:609–613

    Article  PubMed  CAS  Google Scholar 

  27. Engelhardt M, Bertz H, Waller CF, et al. (1999) High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34+ immunoselection. J Clin Oncol 17:2160–2171

    PubMed  CAS  Google Scholar 

  28. Facon T, Harousseau J-L, Maloisel F, et al. (1999) Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Blood 94:1218–1225

    PubMed  CAS  Google Scholar 

  29. Fischer J, Unkrig C, Ackermann M, et al. (1994) Intra-day CD34+ cell counts depend on time to application and correlate with the resulting G-CSF plasma level after steady-state mobilization of PBPC (abstract). Blood 84 (Suppl 1):82

    Google Scholar 

  30. Fliedner TM, Körbling M, Arnold R, et al. (1979) Collection and cryopreservation of mononuclear blood leukocytes and of CFU-C in man. Exp Hematol 7 (Suppl):398–408

    PubMed  Google Scholar 

  31. Flomenberg N, Devine SM, DiPersio JF, et al. (2005) The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 106:1867–1874

    Article  PubMed  CAS  Google Scholar 

  32. Fritsch G, Scharner D, Fröschl G, et al. (2000) Selection of CD34-positive blood cells for allogeneic transplantation: Approaches to optimize CD34-cell recovery, purity, viability, and T-cell depletion. Onkologie 23:449–456

    Article  PubMed  Google Scholar 

  33. Fritsch P, Schwinger W, Schwantzer G, et al. (2010) Peripheral blood stem cell mobilization with pegfilgrastim compared to filgrastim in children and young adults with malignancies. Pediatr Blood Cancer 54:134–137

    Article  PubMed  Google Scholar 

  34. Fruehauf S, Haas R, Conradt C, et al. (1995) Peripheral blood progenitor cell (PBPC) counts during steady state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy. Blood 85:2619–2626

    PubMed  CAS  Google Scholar 

  35. Gianni AM, Siena S, Bregni M, et al. (1989) Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 2:580–584

    Article  PubMed  CAS  Google Scholar 

  36. Glaspy JA (1999) Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy. Bone Marrow Transplant 23 (Suppl 2):S21–S27

    Article  PubMed  Google Scholar 

  37. Gluckman E (2009) History of cord blood transplantation. Bone Marrow Transplant 44:621–626

    Article  PubMed  CAS  Google Scholar 

  38. Goldberg SL, Mangan KF, Klumpp TR, et al. (1995) Complications of peripheral blood stem cell harvesting: review of 554 PBSC leukaphereses. J Hematother 4:85–90

    Article  PubMed  CAS  Google Scholar 

  39. Goldman J. (1995) Peripheral blood stem cells for allografting. Blood 85:1413–1415

    PubMed  CAS  Google Scholar 

  40. Gratwohl A, Baldomero H, Schwendener A, et al. (2009) The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 43:275–291

    Article  PubMed  CAS  Google Scholar 

  41. Grigg AP, Roberts AW, Raunow H, et al. (1995) Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 86:4437–4445

    PubMed  CAS  Google Scholar 

  42. Gutensohn K, Serke S, Cassens U, et al. (1996) Durchflusszytometrische Analyse CD34-exprimierender hämatopoetischer Zellen in Blut und Zytaphereseprodukten. Infusionsther Tranfusionsmed 23 (Suppl 2):1–23

    Google Scholar 

  43. Haas R, Ehrhardt R, Witt B, et al. (1993) Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin’s lymphoma. Bone Marrow Transplant 12:643–649

    PubMed  CAS  Google Scholar 

  44. Haas R, Möhle R, Fruehauf S, et al. (1994) Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83:3787–3794

    PubMed  CAS  Google Scholar 

  45. Haas R, Witt B, Möhle R, et al. (1995) Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 85:3754–3761

    PubMed  CAS  Google Scholar 

  46. Handgretinger R, Klingebiel T, Lang P, et al. (2001) Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 27:777–783

    Article  PubMed  CAS  Google Scholar 

  47. Hasenclever D, Sextro M (1996) Safety of AlloPBPCT donors: biometrical considerations on monitoring long-term risks. Bone Marrow Transplant 17 (Suppl 2):28–30

    Google Scholar 

  48. Heil G, Hoelzer D, Sanz MA, et al. (2002) Long-term survival from a phase 3 study of Filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia (abstract). Blood 100:5

    Google Scholar 

  49. Hepburn MD, Nagesh K, Heppleston AD (2001) Timing of the appearance of multipotential and committed haemopoietic progenitors in peripheral blood after mobilization in patients with lymphoma. Clin Lab Haematol 23:119–124

    Article  PubMed  CAS  Google Scholar 

  50. Herbert KE, Prince HM, Ritchie DS, et al. (2010) The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution. Expert Opin Biol Ther 10:113–125

    Article  PubMed  CAS  Google Scholar 

  51. Hitzler WE, Wolf S, Runkel S, Kunz-Kostomanolakis M (2001) Comparison of intermittent- and continuous-flow cell separators for the collection of autologous peripheral blood progenitor cells in patients with hematologic malignancies. Transfusion 41:1562–1566

    Article  PubMed  CAS  Google Scholar 

  52. Höglund M, Smedmyr B, Simonsson B, et al. (1996) Dose-dependent mobilization of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHu-CSF. Bone Marrow Transplant 18:19–27

    PubMed  Google Scholar 

  53. Hölig K, Kramer M, Kroschinsky F, et al. (2009) Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 114:3757–3763

    Article  PubMed  CAS  Google Scholar 

  54. Humpe A, Riggert J, Meineke I, et al. (2000) A cell-kinetic model of CD34+ cell mobilization and harvest: Development of a predictive algorithm for the CD34+ cell yield in PBPC collections. Transfusion 40:1363–1370

    Article  PubMed  CAS  Google Scholar 

  55. Jacquy C, Sorée A, Lambert F, et al. (2000) A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin’s lymphoma: one-half of patients significantly mobilize malignant cells. Br J Haematol 110:631–637

    Article  PubMed  CAS  Google Scholar 

  56. Kawachi Y, Watanabe A, Uchida T, et al. (1996) Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor. Br J Haematol 94:413–416

    Article  PubMed  CAS  Google Scholar 

  57. Kessinger A, Armitage JO, Landmark JD, et al. (1986) Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol 14:192–196

    PubMed  CAS  Google Scholar 

  58. Ketterer N, Salles G, Moullet I, et al. (1998) Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 103:235–242

    Article  PubMed  CAS  Google Scholar 

  59. Kiss JE, Rybka WB, Winkelstein A, et al. (1997) Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 19:303–310

    Article  PubMed  CAS  Google Scholar 

  60. Körbling M, Ross WM, Pflieger H, et al. (1977) Procurement of human blood stem cells by continuous-flow centrifugation – further comment. Blood 50:753–754

    PubMed  Google Scholar 

  61. Körbling M, Dörken B, Ho AD, et al. (1986) Autologous transplantation of blood derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt’s lymphoma. Blood 67:529–532

    PubMed  Google Scholar 

  62. Körbling M, Przepiorka D, Huh YO, et al. (1995) Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. Blood 85:1659–1665

    PubMed  Google Scholar 

  63. Kolb HJ (2008) Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112:4371–4383

    Article  PubMed  CAS  Google Scholar 

  64. Kolb HJ, Mittermüller J, Clemm C, et al. (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462–2465

    PubMed  CAS  Google Scholar 

  65. Kröger N, Zander AR (2002) Dose and schedule effect of G-CSF for stem cell mobilization in healthy donors for allogeneic transplantation. Leuk Lymphoma 43:1391–1394

    Article  PubMed  CAS  Google Scholar 

  66. Kroschinsky F, Hölig K, Ehninger G (2008) The role of pegfilgrastim in mobilization of hematopoietic stem cells. Transfus Apher Sci 38:237–244

    Article  PubMed  Google Scholar 

  67. Kuendgen A, Fenk R, Bruns I, et al. (2006) Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 38:69–70

    Article  PubMed  CAS  Google Scholar 

  68. Lane TA, Law P, Maruyama M, et al. (1995) Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 85:275–282

    PubMed  CAS  Google Scholar 

  69. Lemoli RM, Fogli M, Fortuna A, et al. (1993) Interleukin-11 stimulates the proliferation of human hematopoietic CD34+ and CD33-DR-cells and synergizes with stem cell factor, interleukin-3, and granulocyte-macrophage colony-stimulating factor. Exp Hematol 21:1668–1672

    PubMed  CAS  Google Scholar 

  70. Lemoli RM, Fortuna A, Motta MR, et al. (1996) Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood 87:1625–1634

    PubMed  CAS  Google Scholar 

  71. Lie AKW, Hui CH, Rawling T (1998) Granulocyte colony-stimulating factor (G-CSF) dose-dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF. Bone Marrow Transplant 22:853–857

    Article  PubMed  CAS  Google Scholar 

  72. Liles WC, Rodger E, Broxmeyer HE, et al. (2005) Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 45:295–300

    Article  PubMed  CAS  Google Scholar 

  73. Malachowski ME, Comenzo RL, Hillyer CD, et al. (1992) Large volume leukapheresis for peripheral blood stem cell collection in patients with hematologic malignancies. Transfusion 32:732–735

    Article  PubMed  CAS  Google Scholar 

  74. Maximow A (1909) Der Lymphozyt als gemeinsame Stammzelle der verschiedenen Blutelemente in der embryonalen Entwicklung und im postfetalen Leben der Säugetiere. Folia Haematol 8:125–141

    Google Scholar 

  75. Moog R (2002) Harvesting of CD34 antigen-expressing cells with a new programme for the collection of mononuclear cells with use of the Amicus (Baxter) blood cell separator. Transfus Med 12:367–372

    Article  PubMed  CAS  Google Scholar 

  76. Müller SM, Schulz AS, Reiss UM, et al. (1999) Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children. Bone Marrow Transplant 24:575–581

    Article  PubMed  Google Scholar 

  77. Mutis T, Goulmy E (2002) Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies. Semin Hematol 39:23–31

    Article  PubMed  Google Scholar 

  78. Nervi B, Link DC, DiPersio JF (2006) Cytokines and hematopoietic stem cell mobilization. J Cell Biochem 99:690–705

    Article  PubMed  CAS  Google Scholar 

  79. Nussbaumer W, Schönitzer D, Trieb T, et al. (1996) Peripheral blood stem cell (PBSC) collection in extremely low-weight infants. Bone Marrow Transplant 18:15–17

    PubMed  CAS  Google Scholar 

  80. Ottinger HD, Beelen DW, Scheulen B, et al. (1996) Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 88:2775–2779

    PubMed  CAS  Google Scholar 

  81. Pecora Al, Preti RA, Gleim GW, et al. (1998) CD34+ CD33-cells influence days to engraftment and transfusion requirements in autologous blood stem cell recipients. J Clin Oncol 16:2093–2104

    PubMed  CAS  Google Scholar 

  82. Porter DL, Antin JH (1999) The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med 50:369–386

    Article  PubMed  CAS  Google Scholar 

  83. Pratt G, Rawstron AC, English AE, et al. (2001) Analysis of CD34+ cell subsets in stem cell harvests can more reliably predict rapidity and durability of engraftment than total CD34+ cell dose, but steady state levels do not correlate with bone marrow reserve. Br J Haematol 114:937–943

    Article  PubMed  CAS  Google Scholar 

  84. Pulsipher MA, Chitphakdithai P, Miller JP, et al. (2009) Adverse events among 2408 unrelated donors of peripheral blood stem cells: Results of a prospective trial from the National Marrow Donor Program. Blood 113:3604–3611

    Article  PubMed  CAS  Google Scholar 

  85. Reiffers J, Bernard PH, David B, et al. (1986) Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. Exp Hematol 14:312–315

    PubMed  CAS  Google Scholar 

  86. Reiffers J, Labopin M, Sanz M., et al. (2000) Autologous blood cell vs. marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis. Bone Marrow Transplant 25:1115–1119

    Article  PubMed  CAS  Google Scholar 

  87. Relling MV, Boyett JM, Blanco JG, et al. (2003) Granulocyte-colony stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 101:3862–3867

    Article  PubMed  CAS  Google Scholar 

  88. Richman CM, Weiner RS, Yankee RA (1976) Increase in circulating stem cells following chemotherapy in man. Blood 47:1031–1034

    PubMed  CAS  Google Scholar 

  89. Roberts AW, DeLuca E, Begley CG, et al. (1995) Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. Stem Cells 13:512–516

    Article  PubMed  CAS  Google Scholar 

  90. Ruiz Arguelles GJ, Ruiz Arguelles A, Perez Romano B, et al. (1995) Filgrastim mobilized peripheral blood stem cells can be stored at 4 °C and used in autografts to rescue high-dose chemotherapy. Am J Hematol 48:100–103

    Article  PubMed  CAS  Google Scholar 

  91. Schmitz N, Linch DC, Dreger P, et al. (1996) Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 347:353–357

    Article  PubMed  CAS  Google Scholar 

  92. Schmitz N, Bacigalupo A, Hasenclever D, et al. (1998) Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21:995–1003

    Article  PubMed  CAS  Google Scholar 

  93. Schreiner T, Maccari B, Erne E, et al. (1996) Highly effective CD34 positive selection of G-CSF mobilized allogeneic peripheral blood progenitor cells. Blood 88:1517–1518

    PubMed  CAS  Google Scholar 

  94. Schreiner T, Wiesneth M, Krug E, et al. (1998) Collection of allogeneic peripheral blood progenitor cells by two protocols on an apheresis system. Transfusion 38:1051–1055

    Article  PubMed  CAS  Google Scholar 

  95. Schulman, KA, Birch R, Zhen B, et al. (1999) Effect of CD34+ cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol 17:1227–1233

    PubMed  CAS  Google Scholar 

  96. Smith TJ, Hillner BE, Schmitz N, et al. (1997) Economic analysis of a randomized clinical trial to compare filgrastim-mobilised peripheralblood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin’s and non-Hodgkin’s lymphoma. J Clin Oncol 15:5–10

    PubMed  CAS  Google Scholar 

  97. Socinski MA, Cannistra SA, Elias A, et al. (1988) Granulocyte-macrophage colony stimulating factor expands the circulating hematopoietic progenitor cell compartment in man. Lancet 1:1194–1198

    Article  PubMed  CAS  Google Scholar 

  98. Stadmauer EA, Schneider CJ, Silberstein LE (1995) Peripheral blood progenitor cell generation and harvesting. Semin Oncol 22:291–300

    Google Scholar 

  99. Stiff P (1999) Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant 23 (Suppl 2):S29–S33

    Article  PubMed  Google Scholar 

  100. Stiff P, Gingrich R, Luger S, et al. (2000) A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin’s disease or non-Hodgkin’s lymphoma. Bone Marrow Transplant 26:471–481

    Article  PubMed  CAS  Google Scholar 

  101. Stroncek DF, Clay ME, Herr G, et al. (1997) Blood counts in healthy donors 1 year after the collection of granulocyte-colony-stimulating factor-mobilized progenitor cells and the results of a second mobilization and collection. Transfusion 37:304–308

    Article  PubMed  CAS  Google Scholar 

  102. Stroncek DF, Clay ME, Herr G, et al. (1997) The kinetics of G-CSF mobilization of CD34+ cells in healthy people. Transfus Med 7:19–24

    Article  PubMed  CAS  Google Scholar 

  103. Stroncek DF, Clay ME, Jaszcz W, et al. (1999) Collection of two peripheral blood stem cell concentrates from healthy donors. Transfus Med 9:37–50

    Article  PubMed  CAS  Google Scholar 

  104. Sutherland DR, Anderson L, Keeney M, et al. (1996) The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 5:213–226

    Article  PubMed  CAS  Google Scholar 

  105. Testoni N, Lemoli RM, Martinelli G, et al. (1998) Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients: evluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods. Bone Marrow Transplant 22:1065–1070

    Article  PubMed  CAS  Google Scholar 

  106. Tichelli A, Passweg J, Hoffmann T, et al. (1999) Repeated peripheral stem cell mobilization in healthy donors: time-dependent changes in mobilization efficiency. Brit J Haematol 106:152–158

    Article  CAS  Google Scholar 

  107. Urbano-Ispizua A, Schmitz N, de Witte T, et al. (2002) Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 29:639–646

    Article  PubMed  CAS  Google Scholar 

  108. Van der Wall E, Richel DJ, Holtkamp MJ, et al. (1994) Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood cell transplantation: effect of graft size. Ann Oncol 5:795–802

    PubMed  Google Scholar 

  109. Waller CF, Bertz H, Wenger MK, et al. (1996) Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimen. Bone Marrow Transplant 18:279–283

    PubMed  CAS  Google Scholar 

  110. Weaver CH, Birch R, Greco FA, et al. (1998) Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol 100:338–347

    Article  PubMed  CAS  Google Scholar 

  111. Welte K, Gabrilove J, Bronchud MH, et al. (1996) Filgrastim (rmetHuGCSF): the first 10 years. Blood 88:1907–1929

    PubMed  CAS  Google Scholar 

  112. Wiesneth M, Schreiner T, Friedrich W, et al. (1996) Combined CD34-positive plus CD2-negative selection for effective T-cell depletion as GvHD-prophylaxis in HLA-nonidentical blood progenitor cell transplantation. Transfus Sci 17:629–635

    PubMed  CAS  Google Scholar 

  113. Wiesneth M, Schreiner T, Sandherr M, et al. (1997) Haematopoietic reconstitution after autologous transplantation of CD34+-selected versus non-selected peripheral blood progenitor cells. Beitr Infusionsther Transfusionsmed 34:133–138

    PubMed  CAS  Google Scholar 

  114. Wiesneth M, Schreiner T, Friedrich W, et al. (1998) Mobilization and collection of allogeneic peripheral blood progenitor cells for transplantation. Bone Marrow Transplant 21 (Suppl 3):S21–S24

    PubMed  Google Scholar 

  115. Wiesneth M, Müller C, Schrezenmeier H (2007) Spendersicherheit bei der Mobilisation und Entnahme von peripheren Blutstammzellen. Hämotherapie 10:22–35 (www.drk.de/blutspende)

    Google Scholar 

  116. Wu MH, Smith SL, Danet GH, et al. (2001) Optimization of culture conditions to enhance transfection of human CD34+ cells by electroporation. Bone Marrow Transplant 27:1201–1209

    Article  PubMed  CAS  Google Scholar 

  117. Deutsche Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI) (1998) Empfehlungen zur Blutstammzellapherese der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI). Infusionsther Transfusionsmed 25:325–335

    Google Scholar 

  118. Deutsche Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI) (2002) Ergänzung für die »Empfehlungen zur Blutstammzellapherese « der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI). Infusionsther Transfusionsmed 29:38–39

    Google Scholar 

  119. Europäisches Arzneibuch, 6. Ausgabe, Grundwerk 2008, Band 1: Allgemeiner Teil: Monographiegruppen

    Google Scholar 

  120. Foundation for the Accreditation of Cellular Therapy (FACT) and Joint Accreditation Committee ISCT - EBMT (JACIE) (2009)International Standards for Cellular Therapy Product Collection, Processing, and Administration – Accreditation Manual. 4th edn, version 4.1

    Google Scholar 

  121. Genehmigung nach § 21a AMG für Stammzellzubereitungen beim Paul-Ehrlich-Institut (www.pei.de– Antragsteller und Pharmazeutischer Unternehmer/Genehmigung von Geweben und Stammzellen (human)/Regelungen für Stammzellzubereitungen)

  122. Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz – AMG) Neufassung vom 12.12.2005 BGBI. I (2005):3394 ff; zuletzt geändert durch Art. 1 V v. 28.9.2009, BGBl. I (2009):3172 ff (3578)

    Google Scholar 

  123. Gesetz über Medizinprodukte (Medizinproduktegesetz – MPG) Neufassung vom 7.8.2002, BGBI. I (2002):3146 ff; zuletzt geändert durch Art. 6 G v. 29.7.2009, BGBl. I (2009):2326 ff

    Google Scholar 

  124. Gesetz zur Regelung des Transfusionswesens (Transfusionsgesetz – TFG) Neufassung vom 28.8.2007 BGBI. I (2007):2169 ff; geändert durch Art. 12 G v. 17.7.2009 BGBl. I (2009):1990 ff

    Google Scholar 

  125. Guidelines for the collection, processing and storage of human bone marrow and peripheral stem cells for transplantation (1994). Prepared by the BCSH Blood Transfusion Task Force. Transfus Med 4:165–172

    Article  Google Scholar 

  126. Richtlinien zur Transplantation peripherer Blutstammzellen (1997) Erarbeitet vom Wissenschaftlichen Beirat der Bundesärztekammer unter Mitwirkung des Paul-Ehrlich-Institutes. Dtsch Ärztebl 94:A1584–A1591

    Google Scholar 

  127. Richtlinie 2003/94/EG der Kommission vom 8. Oktober 2003 zur Festlegung der Grundsätze und Leitlinien der Guten Herstellungspraxis für Humanarzneimittel und für zur Anwendung beim Menschen bestimmte Prüfpräparate (GMP). Amtsblatt der Europäischen Union L 262/22 bis L 262/26

    Google Scholar 

  128. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie) (2010) Aufgestellt gemäß Transfusionsgesetz von der Bundesärztekammer im Einvernehmen mit dem Paul-Ehrlich-Institut. Zweite Richtlinienanpassung 2010

    Google Scholar 

  129. The European Agency for the Evaluation of Medicinal Products - Evaluation of Medicines for Human Use (2001) Manufacture and quality control of human somatic cell therapy medicinal products

    Google Scholar 

  130. Verordnung über die Anwendung der Guten Herstellungspraxis bei der Herstellung von Arzneimtteln und Wirkstoffen und über die Anwendung der Guten fachlichen Praxis bei der Herstellung von Produkten menschlicher Herkunft (Arzneimittel- und Wirkstoffherstellungsverordnung - AMWHV) vom 3.11.2006 BGBl. I (2006):2523 ff, geändert durch Art. 1 V v. 26.3.2008 BGBl. I (2008):521 ff

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Klinische Transfusionsmedizin und Immungenetik Ulm, Universitätsklinikum Ulm, Helmholtzstraße 10, 89081, Ulm

    Dr. M. Wiesneth

Authors
  1. Dr. M. Wiesneth
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung für Transfusionsmedizin, Universitätsklinikum Rostock AöR, Ernst-Heydemann-Str. 6, 18057, Rostock

    Volker Kiefel

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Wiesneth, M. (2010). Gewinnung und Präparation von peripheren Blutstammzellen. In: Kiefel, V., Mueller-Eckhardt, C. (eds) Transfusionsmedizin und Immunhämatologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12765-6_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-12765-6_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-12764-9

  • Online ISBN: 978-3-642-12765-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation